The PFS benefit of acalabrutinib +-obinutuzumab was observed in CLL patients with del(17p) or TP53 mutations, IGHV-unmutated, and IGHV-mutated CLL [25]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.